Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial

BACKGROUND: Src kinase-mediated interactions between prostate cancer cells and osteoclasts might promote bone metastasis. Dasatinib inhibits tyrosine kinases, including Src kinases. Data suggests that dasatinib kinase inhibition leads to antitumour activity, affects osteoclasts, and has synergy with...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Lancet Oncol
Auteurs principaux: Araujo, John C, Trudel, Géralyn C, Saad, Fred, Armstrong, Andrew J, Yu, Evan Y, Bellmunt, Joaquim, Wilding, George, McCaffrey, John, Serrano, Sergio V, Matveev, Vsevolod B, Efstathiou, Eleni, Oudard, Stephane, Morris, Michael J, Sizer, Bruce, Goebell, Peter J, Heidenreich, Axel, de Bono, Johann S, Begbie, Stephen, Hong, Jun H, Richardet, Eduardo, Gallardo, Enrique, Paliwal, Prashni, Durham, Susan, Cheng, Shinta, Logothetis, Christopher J
Format: Artigo
Langue:Inglês
Publié: 2013
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5478530/
https://ncbi.nlm.nih.gov/pubmed/24211163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(13)70479-0
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires